The Generalist
The Generalist
Shrinking the Gap Between Sci-Fi and Sci-Fact: Josh Wolfe (Co-Founder of Lux Capital)
0:00
-1:27:26

Shrinking the Gap Between Sci-Fi and Sci-Fact: Josh Wolfe (Co-Founder of Lux Capital)

Josh Wolfe on investing in frontier technologies: pig organ transplants, digital smell, and finding “X-Men.”

Friends,

What if you could record the smell of your grandmother’s kitchen or detect diseases with a breath? Josh Wolfe, co-founder of Lux Capital, is funding the breakthroughs that are turning these concepts into reality.

In this episode of The Generalist, Josh discusses how Lux Capital is backing companies like eGenesis, which is transplanting gene-edited pig organs into humans; Osmo, pioneering digital olfaction technology; and Variant Bio, which is studying genetic outliers in indigenous populations whose DNA could lead to life-saving medical advancements.

Science fiction doesn’t just predict the future, it creates it. Josh’s investment approach is deeply influenced by speculative fiction, which has inspired many of the groundbreaking companies in his portfolio. This visionary thinking has driven Lux to fund startups working on technologies once considered impossible.

Josh also shares how stories shape his worldview, how he stays on top of macro trends, where America is trailing China in the AI race, and how we can catch up.

In our conversation, we explore:

  • The revolutionary development of genetically modified pig organs being transplanted into humans and what this means for the future of organ transplantation.

  • The recent achievement of "teleporting smell" across space and why computers that can replicate scents will open up entirely new industries.

  • Why Lux is investing in the search for real-life "X-Men" — genetic outliers in isolated populations whose DNA could lead to life-saving medical advancements.

  • How Josh evaluates macro trends to make smarter micro investment decisions and why ignoring the big picture is a mistake.

  • The three tech sectors that Josh believes will define the geopolitical balance in the decades ahead.

  • How Josh stays current on macroeconomic trends.

  • Much more


Thank you to the partners who make this possible

Brex: The banking solution for startups.
WorkOS
: The modern identity platform for B2B SaaS.
Generalist+: Essential intelligence for modern investors and technologists.


Explore the episode

YouTube

Spotify

Apple

Timestamps

(00:00) Intro

(04:38) A brief overview of Josh’s work at Lux Capital

(05:57) The science fiction to science fact pipeline

(09:11) Xenotransplantation

(12:10) Proven transplantations with modified pig kidneys, and what’s next

(15:38) Ethical questions around xenotransplantation

(17:48) Lux Capital’s investment in eGenesis

(19:34) The theory of persistent cellular memory

(23:35) Why eGenesis began with kidneys

(24:30) Digitizing smell

(32:24) Commercializing digital olfaction technology

(38:26) The potential applications for a “Shazam for smell”

(43:16) Variant Bio’s work studying genetic outliers

(52:00) Variant Bio's two primary clinical focuses

(53:46) How Josh stays current on macroeconomic trends

(59:44) Josh’s thoughts on the critical areas the U.S. should invest in

(1:14:00) How to win the talent war

(1:18:53) Final meditations


Follow Josh Wolfe

X: https://x.com/wolfejosh

LinkedIn: https://www.linkedin.com/in/josh-wolfe-7883/


Resources and episode mentions

Books

People

Other resources


Subscribe to the show

I’d love it if you’d subscribe and share the show. Your support makes all the difference as we try to bring more curious minds into the conversation.

YouTube

Spotify

Apple


Production and marketing by penname.co. For inquiries about sponsoring the podcast, email jordan@penname.co.

Discussion about this episode